A 50-year-old woman was admitted to the emergency room. An appendectomy was done. On the sixth day the patient’s general state deteriorated and she became somnolent with jaundice due to distal obstructive choledocholithiasis. The results of laboratory tests were platelets 12 x 109/L, prothrombin time 13 seconds, international normalized ratio 1.19, activated partial thromboplastin time 31.8 seconds, and fibrinogen 8.78 g/L. There was no evidence of disseminated intravascular coagulation. In view of the patient’s clinical condition, surgery was considered to be indicated. Because it was a life-threatening situation and at the time there was no platelet concentrate available for immediate transfusion, she was treated with a single dose of recombinant factor VIIa (rFVIIa) (60 μg/kg).The dose of 60 μg/kg was selected on the basis of experience with rFVIIa in the treatment of hemophilic patients. In this case, use of rFVIIa was a valid alternative to control the bleeding in a patient with thrombocytopenia. However, despite the efficacy of the treatment, it should not be forgotten that it was used because of the unavailability of platelets and that we were dealing with a life-threatening situation. Clinical trials should be carried out to verify the safety, effectiveness, and efficiency of rFVIIa in these cases.
Recombinant factor VIIa Thrombocytopenia Hemorrhage Surgery Platelets
This is a preview of subscription content, log in to check access.
Vidarsson B, Önundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost. 2000;83:634–635.CrossRefGoogle Scholar
Erhardtsen E. To general haemostasis-the evidence-based route. Pathophysiol Haemost Thromb. 2002;32(suppl 1):47–52.CrossRefGoogle Scholar
Laurian Y. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa? Pathophysiol Haemost Thromb. 2002;32(suppl 1):37–40.CrossRefGoogle Scholar
Slappendel R, Huvers FC, Benraad B, Novakova I, van Hellemondt GG. Use of recombinant factor VIIa (NovoSeven) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia. Anesthesiology. 2002; 96:1525–1527.CrossRefGoogle Scholar
Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 1996;26(suppl 1):159–164.PubMedGoogle Scholar
Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost. 1996;75:981–982.PubMedGoogle Scholar
Gerotziafas GT, Zervas C, Gavrelidis G, et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol. 2002;69:219–222.CrossRefPubMedGoogle Scholar
Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542–547.CrossRefPubMedGoogle Scholar
Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol. 2001;114:114–120.CrossRefGoogle Scholar